Acute lymphoblastic leukemia (ALL) is an aggressive and heterogeneous disease with a high mortality rate. However, several advances have been made in recent years to improve treatment options for patients. Novel immunotherapies, such as chimeric antigen receptor T-cell (CAR-T) therapy and antibodies, are continuously being explored and have greatly changed the treatment landscape.
In this exclusive podcast, you will hear from experts Noelle Frey, MD, MSCE, University of Pennsylvania, Philadelphia, PA, Bijal Shah, MD, Moffitt Cancer Center, Tampa, FL, and Shannon Maude, MD, PhD, Children's Hospital of Philadelphia, Philadelphia, PA, who discuss the future of CAR-T therapy in ALL, highlighting the impact of the approval of tisagenlecleucel (tisa-cel) in adult patients, the promise of allogeneic products, and more. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.
Understanding multiple myeloma at the single-cell level
Recent advances in amyloidosis treatment
ASH 2021: a deep dive into ALL immunotherapy
ASH 2021: what did ASH 2021 mean for MDS?
ASH 2021: novel developments in MPNs
ASH 2021: evaluating the impact of screening for multiple myeloma precursor diseases
ASH 2021: the future of cell therapies in lymphoma
ASH 2021: highlights in CLL clinical trials
ASH 2021: updates in FLT3-mutated AML
The Lymphoma Sessions: post-ASH 2021
COSTEM: maintenance therapies for FLT3+ AML
COSTEM: the role of alloHSCT in ALL
SOHO 2021: amyloidosis treatment updates
IACH 2021: CAR-T in clinical practice
Unmet needs and recent updates in CML
IMW 2021: treatment-free intervals in multiple myeloma
Highlights from iwCLL 2021
IMW 2021: MRD in myeloma
CAR-T vs bispecifics: replacing ASCT in myeloma
EHA 2021: antibody therapies for NHL
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive